Constellation Pharmaceuticals, Inc.
CNST
CNST was delisted on the 14th of July, 2021.
132 hedge funds and large institutions have $1.44B invested in Constellation Pharmaceuticals, Inc. in 2020 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 56 increasing their positions, 19 reducing their positions, and 12 closing their positions.
1,203% more call options, than puts
Call options by funds: $23M | Put options by funds: $1.77M
275% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 12
195% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 19
33% more funds holding
Funds holding: 99 → 132 (+33)
16% more capital invested
Capital invested by funds: $1.25B → $1.44B (+$196M)
25% less funds holding in top 10
Funds holding in top 10: 12 → 9 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$74.1M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$54.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$37M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$30.2M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$26.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$64.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$30.3M |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$28.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$22.6M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$19.6M |
CNST Hedge Fund Activity: Q2 2020 in Review
132 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q2 2020, worth a combined $1.44B — up 16% from $1.25B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new CNST positions and 12 closed out — a net gain of 33 holders — while 56 added to existing stakes and 19 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $74.1M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $64.1M sold.
- 132 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q2 2020, up from 99 in Q1 2020.
- Funds reported $1.44B of Constellation Pharmaceuticals, Inc. stock for Q2 2020, up 16% quarter-over-quarter.
- 45 funds opened new Constellation Pharmaceuticals, Inc. positions in Q2 2020 and 12 closed out, a net change of +33 holders.
- The largest Constellation Pharmaceuticals, Inc. buyer in Q2 2020 was Wellington Management Group, an estimated $74.1M added.
- The largest Constellation Pharmaceuticals, Inc. seller in Q2 2020 was Cormorant Asset Management, an estimated $64.1M sold.
Based on aggregated 13F filings for Q2 2020.